Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
ID: 335547Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/335547

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)" aimed at supporting pilot and exploratory research addressing urgent issues related to substance use. This initiative focuses on five priority areas, including responses to sudden spikes in drug abuse, emerging marijuana trends, and time-sensitive opportunities in health care and justice systems, necessitating an expedited review process for applications. The funding amount is capped at $275,000 over a two-year period, with applications due by January 14, 2025. Eligible applicants include a diverse range of organizations, and inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-027-Full-Announcement.html
    PAR-22-027.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and particularly the National Institute on Drug Abuse (NIDA), has announced the funding opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)”. This initiative supports pilot and exploratory research that addresses urgent and emerging issues related to substance use, including spikes in drug abuse and the implications of public health emergencies such as the opioid crisis and the COVID-19 pandemic. Funding is provided for research that is time-sensitive, requiring an expedited review process, with applications due by January 13, 2025, for projects with a maximum budget of $275,000 over two years. Eligible applicants include various organizations, such as higher education institutions, nonprofits, and local governments. The application process necessitates adherence to strict guidelines regarding research methodology, participant inclusion, and data sharing. The overarching goal is to strengthen the response to urgent drug-related issues through partnerships between researchers and community organizations while enhancing the understanding of evolving contexts in health care and justice systems. This FOA represents NIH’s commitment to addressing pressing public health challenges through innovative research collaborations.
    Similar Opportunities
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data," aimed at supporting innovative analyses of existing datasets related to substance use behaviors, including alcohol, tobacco, and illicit drugs, and their connections to health outcomes such as HIV. This grant, classified as an R21 Clinical Trial Not Allowed, encourages applicants to utilize existing social science, behavioral, administrative, and neuroimaging data to enhance understanding of drug use behaviors, their consequences, and effective prevention and treatment strategies. A total of $2 million is available for projects over a two-year period, with individual application budgets capped at $275,000. Interested applicants must submit their proposals electronically through Grants.gov by December 3, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis," aimed at supporting research that translates findings into practical solutions for addressing the overdose crisis. This initiative encourages applications from a diverse range of organizations, including educational institutions and nonprofits, with a focus on developing stigma-free, patient-centered systems for addiction recovery and improving the quality of addiction treatment services. The NIH plans to commit approximately $10 million to fund grants, with an expected award ceiling of $750,000 for up to 12 awards, and applications will be accepted starting February 20, 2025, with a closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-077.html.
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.